Start from the patient and work backwards, using Figure A and other details mentioned in the case. HINT: ultimate power will be with the party that is making the payment. b. Based on this analysis, you should be able to address whether CVS should compromise with or take on Merck Medco. 3.
Diabetes. Retrieved April 13, 2011, from http://www.diabetes.org/diabetes-basics/type-1 National Institutes of Health. (2011). Type 2 diabetes. Retrieved April 13, 2011, from http://www.nlm.nih.gov/medlineplus/ency/article/000313 National Institutes of Health.
Second, the utility test will be applied to determine what action will result in the best outcome for all affected. Third, the issue will be measured using the virtue test to resolve whether the transistor company’s actions fulfill their vision of who they seek to be. Finally, the results from the two ethics tests will be compared to resolve which of the tests was the most informative to the case. Using these tools will demonstrate that the ethical choice for the company is to sell transistors to the pacemaker company. The first step is to examine the issues using the utilitarian ethics framework.
Evaluation of clinical practice guideline on the management of lipids as a cardiovascular risk factor Brooke Bevis Simmons College Evaluation of clinical practice guideline on the management of lipids as a cardiovascular risk factor I chose to evaluate Clinical practice guidelines on the management of lipids as a cardiovascular risk factor. The objective of this guideline was “to formulate recommendations that will aid decision-making on lipid management as a cardiovascular risk (CVR) factor” (National Guideline Clearinghouse [NGC], 2013, p. 2). The guideline was intended to “improve health care for CVR patients by suggesting options that are more beneficial to them, based on focusing attention on the best tests and evidence available in scientific literature” and to “diminish the differences observed in the treatment and management of lipids as a CVR factor in clinical practice by bringing the best evidence closer to clinical decision-making.” (NGC, 2013, p. 2). The target population included patients at increased risk for cardiovascular disease (CVD) (NGC, 2013). Interventions and practices considered included categories of: diagnosis/evaluation/ risk assessment and management/treatment/prevention (NGC, 2013).
ENDOCRYTE IPO ANALYSIS The company that I chose to conduct my IPO on is called Endocyte. Endocyte just went public in July 2011 and is currently being traded on the NASDAQ with a Global Market symbol of (ECYT). Here is a little background on Endocyte as a company as well as the industry they are in: Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. The company uses proprietary technology to create novel small molecule drug conjugates, or SMDCs, and companion imaging diagnostics. SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells.
This can allow providers to avoid re-admission, avoiding medication errors, lower duplication testing and improve diagnosis. If a practice successfully integrated faxing medical records, they may inquire, why they should switch over to the electronic health information exchange, but the betterment exist with information exchange regardless of the means which it’s transferred. The importance of electronic exchange is to standardization of data. This means, once the data is standardized, the data that’s transferred will simply be incorporated into the receiver’s Electronic health record also known as EHR in which this can better patient care. For instance, if a lab results for diabetes are received through the HIE system it can be fused into the providers EHR and a list of patients with diabetes can be created and the physician can conclude which patient have uncontrollably blood sugar and need schedule a follow up if needed.
Table of Content 1 Introduction 2 2 Socially responsible and ethical manner 3 2.1 Drug development and testing 4 2.2 Marketing and advertising 5 2.3 Relationship with government regulators 5 2.4 Handling of the recall 6 3 Role of stakeholders 7 3.1 Pharmaceutical companies 7 3.2 Government regulator and policy maker 8 3.3 Patients and their physicians 9 3.4 The court system 10 4 Suggestion for improvement 11 5 Conclusion 13 6 References 15 1 Introduction The purpose of conducting the Merck, The FDA, and the Vioxx Recall case studies to identifying certain issues regarding the Merck and vioxx. The objective of the case studies is identify whether the Merck, the company CEO is responsible and has ethical manner or not. Besides that, the purpose of conducting the case study is to research on how Merck did drug and development testing, what method and how Merck did marketing and advertising, the relationship of Merck with government regulator and policymaker and how does Merck handling the recall of vioxx. Besides that the purpose of conducting the research on the case study is also to identify the role of stake holder to the pharmaceutical firms. What is the role of pharmaceutical companies.
Smart pumps, particularly Carefusion’s Alaris SE pump, runs the guardrails suite MX software. This smart pump along with others like it, are medication infusion devices. These types of devices contain programmed drug libraries with standardized medication concentrations, for the most commonly used drugs. These smart pumps are programmed by the hospital pharmacy with the types of IV medications, along with concentration and standard dosing. Before administration can begin, the caregiver must choose the desired medication along with the concentration from the library.
This assignment will use the Gibbs (1988) model of reflection to reflect upon a Health promotion activity undertaken in a secondary care setting. This model encourages clear description of the event, analysis and evaluation of the situation and to draw a conclusion considering relative information. It will look at how smoking cessation advice was delivered to a patient giving consideration to relevant literature which supports the associated health benefits. For the purpose of this essay I have used the pseudonym Charles to protect the patients’ identity, this complies with the Nursing and Midwifery Council (NMC) (2008) ‘The Code’ which concludes that people have the right to confidentiality. It is first important to understand the concept of health promotion in today’s environment.
Below is the first part of your Marketing Plan Report: QUESTION 1 You have to submit the first part of your Marketing Plan Report that covers among other things: 1. Situation Analyses, this will include: a) Situational environments (such as demand trends for your product/service; your customers; the decision makers; social and cultural factors involved; are demographic important here; state-of-art technology effects; politics and economic effects). b) Neutral environments, this has to do with groups or organizations. Media reports (favourable or unfavourable), consumer associations, and legislations. How do they have effect (if any) on your marketing plan for your product?